Cantor Fitzgerald Issues Positive Estimate for TSHA Earnings

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Analysts at Cantor Fitzgerald lifted their FY2025 earnings per share estimates for Taysha Gene Therapies in a report released on Monday, May 19th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will post earnings per share of ($0.36) for the year, up from their prior estimate of ($0.38). Cantor Fitzgerald currently has a "Overweight" rating and a $7.00 target price on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.35) per share.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.30 million for the quarter, compared to analyst estimates of $1.48 million. During the same period in the previous year, the firm posted ($0.10) EPS.

Other analysts also recently issued reports about the company. Needham & Company LLC reissued a "buy" rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, April 10th. Chardan Capital reissued a "buy" rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. JMP Securities reiterated a "market outperform" rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Finally, Canaccord Genuity Group boosted their price target on Taysha Gene Therapies from $8.00 to $9.00 and gave the stock a "buy" rating in a research report on Friday, May 16th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and an average price target of $6.57.

Taysha Gene Therapies Stock Down 3.5%

Shares of NASDAQ:TSHA traded down $0.10 during trading on Wednesday, reaching $2.75. 4,063,290 shares of the stock were exchanged, compared to its average volume of 2,904,801. Taysha Gene Therapies has a 1-year low of $1.05 and a 1-year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The stock has a fifty day moving average of $1.83 and a two-hundred day moving average of $1.86. The firm has a market cap of $563.90 million, a price-to-earnings ratio of 4.37 and a beta of 0.90.

Hedge Funds Weigh In On Taysha Gene Therapies

A number of large investors have recently added to or reduced their stakes in TSHA. Ground Swell Capital LLC acquired a new position in Taysha Gene Therapies in the fourth quarter valued at approximately $25,000. Cibc World Markets Corp acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth about $28,000. E Fund Management Co. Ltd. acquired a new stake in shares of Taysha Gene Therapies during the fourth quarter worth $31,000. Hsbc Holdings PLC lifted its holdings in shares of Taysha Gene Therapies by 65.6% in the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after buying an additional 8,076 shares during the period. Finally, AXQ Capital LP acquired a new stake in shares of Taysha Gene Therapies in the fourth quarter valued at about $39,000. 77.70% of the stock is currently owned by institutional investors and hedge funds.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.